VAN-2201: Phase 1 study of KH631 gene therapy for the treatment of wet AMD (NCT05657301)

KH631 - Chengdu Kanghong Pharma

Stephen Huddleston1,2; Shawn Patrick Shearn4; Anna Maria Oughton4; Corrine Winters4; Qiang Zheng3; Xiao Ke3; Avner Ingerman4

Mar 26, 2025